EP4709727A1 - Verfahren und zusammensetzungen für gezielten proteinabbau - Google Patents
Verfahren und zusammensetzungen für gezielten proteinabbauInfo
- Publication number
- EP4709727A1 EP4709727A1 EP24735385.7A EP24735385A EP4709727A1 EP 4709727 A1 EP4709727 A1 EP 4709727A1 EP 24735385 A EP24735385 A EP 24735385A EP 4709727 A1 EP4709727 A1 EP 4709727A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- compound
- het
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023093091 | 2023-05-09 | ||
| PCT/US2024/028674 WO2024233838A1 (en) | 2023-05-09 | 2024-05-09 | Methods and compositions for targeted protein degradation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4709727A1 true EP4709727A1 (de) | 2026-03-18 |
Family
ID=91621253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24735385.7A Pending EP4709727A1 (de) | 2023-05-09 | 2024-05-09 | Verfahren und zusammensetzungen für gezielten proteinabbau |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4709727A1 (de) |
| CN (1) | CN121487938A (de) |
| WO (1) | WO2024233838A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| KR20260087586A (ko) | 2023-10-03 | 2026-06-11 | 피에이큐 테라퓨틱스 인코포레이티드 | Kras 단백질분해 표적화 키메라 |
| WO2025103476A1 (zh) * | 2023-11-15 | 2025-05-22 | 上海医药集团股份有限公司 | 一种靶向蛋白调节剂的化合物及其应用 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026114957A1 (en) | 2024-11-27 | 2026-06-04 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer |
| US20260146050A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4332105A4 (de) * | 2021-04-30 | 2025-05-28 | Genfleet Therapeutics (Shanghai) Inc. | Pyridino- oder pyrimidocyclische verbindung, herstellungsverfahren dafür und medizinische verwendung davon |
| WO2022266206A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| EP4417606A4 (de) * | 2021-10-15 | 2025-10-22 | Sunshine Lake Pharma Co Ltd | Neue pyrimidopyridinverbindung, pharmazeutische zusammensetzung daraus und verwendung davon |
-
2024
- 2024-05-09 EP EP24735385.7A patent/EP4709727A1/de active Pending
- 2024-05-09 WO PCT/US2024/028674 patent/WO2024233838A1/en not_active Ceased
- 2024-05-09 CN CN202480046359.4A patent/CN121487938A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN121487938A (zh) | 2026-02-06 |
| WO2024233838A1 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2024233838A1 (en) | Methods and compositions for targeted protein degradation | |
| WO2023081476A1 (en) | Methods and compositions for targeted protein degradation | |
| US20240116950A1 (en) | Inhibitors of kras(g12d) | |
| WO2024044334A2 (en) | Methods and compositions for modulating kras(g12d) | |
| EP4305037B1 (de) | Kras inhibitoren | |
| WO2024123913A1 (en) | Kras(g12v) inhibitors | |
| WO2023220421A1 (en) | Inhibitors of kras(g12d) | |
| CN113939516B (zh) | 用于靶向蛋白降解的方法和组合物 | |
| WO2024227091A1 (en) | Diazabicyclooctane inhibitors of kras (g12d) and uses | |
| WO2024118926A1 (en) | 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-pyrido[4,3-d]pyrimidine derivatives as inhibitors of the kras(g12d) mutant oncoprotein for the treatment of cancer | |
| KR20230019101A (ko) | 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도 | |
| WO2022192794A1 (en) | Kras g12d inhibitors | |
| WO2025019666A1 (en) | Methods and compositions for modulating shp2 | |
| AU2021362975A1 (en) | Methods and compositions for targeted protein degradation | |
| EP4228700A1 (de) | Verfahren und zusammensetzungen für gezielten proteinabbau | |
| EP4687908A1 (de) | Verfahren und zusammensetzungen für gezielten proteinabbau | |
| CN117003754A (zh) | 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途 | |
| EP4229061A1 (de) | Verfahren und zusammensetzungen für gezielten proteinabbau | |
| CN116836167A (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| RU2820673C2 (ru) | Способы и композиции для направленной деградации белка | |
| WO2025199665A1 (en) | Methods and compositions for targeted protein degradation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251209 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) |